

## Information Letter of the ELN: Editor Statements

**Please read and send/fax your agreement (2 pages) back to:**

European Leukemia Information Center ELIC  
Dr. N. Gökbüget / A. Hellenbrecht / K. Ihrig  
University Clinic of Frankfurt  
Dept. of Hematology / Oncology  
Theodor-Stern Kai 7  
60590 Frankfurt am Main, Germany  
Phone: +49(0)69 6301 -6365

**Fax: +49-(0)69 6301 -7463**

E-mail: [elic@leukemia-net.org](mailto:elic@leukemia-net.org)  
Internet: [www.leukemia-net.org](http://www.leukemia-net.org)  
[www.kompetenznetz-leukaemie.de](http://www.kompetenznetz-leukaemie.de)

### 1. Basic Information

The IL presents results from the collaboration of transnational leukemia study groups. This is not only of interest for clinicians and researchers in the field of hematology throughout Europe, but also worldwide. Major goals are target and drug discovery, support of clinical translation, application of genomics and promotion of clinical trials. Furthermore, meta-analyses, elaboration of prognostic scores and guidelines for diagnostics and treatment will be promoted throughout Europe.

Authors are invited by the Editorial Board and are following the Editor statements (signed agreement of the responsible authors).

### 2. Informed Consent

Identifying information, including patients' names, initials, or hospital numbers, are not be published in written descriptions, photographs, and pedigrees unless the information is essential for scientific purposes and the patient (or parent or guardian) gives written informed consent for publication. Informed consent for this purpose requires that a patient who is identifiable be shown the manuscript to be published. Authors have to identify Individuals who provide writing assistance and disclose the funding source for this assistance.

Identifying details should be omitted if they are not essential and informed consent should be obtained if there is any doubt about anonymity. If identifying characteristics are altered to protect anonymity, such as in genetic pedigrees, authors have to provide assurance that alterations do not distort scientific meaning.

### 3. Conflict of interest

It has been the policy of the European LeukemiaNet not to promote the pharmaceutical industry, their products and/or services in the IL for advertisement.

The selection and review of authors articles are free of influence by financial or personal relationships of the Editorial Board. Authors are asked about having conflict of interest regarding the research project. If a conflict of interest of the author is possible, this will be published.

#### **4. Human and animal rights**

When reporting experiments on human subjects, authors have to indicate whether the procedures followed were in accordance with the ethical standards of the responsible committee on human experimentation (institutional and national) and with the Helsinki Declaration of 1975, as revised in 2000. If doubt exists whether the research was conducted in accordance with the Helsinki Declaration, the authors must explain the rationale for their approach, and demonstrate that the institutional review body explicitly approved the doubtful aspects of the study. When reporting experiments on animals, authors are asked to indicate whether the institutional and national guide for the care and use of laboratory animals was followed and this will be published.

#### **5. Editorial Board**

Marie C. Béné  
Steven O'Brien  
Alan Burnett  
Guido Finazzi  
Christa Fonatsch  
Eliane Gluckman  
Nicola Gökbuget (Editor-in-Chief)  
David Grimwade  
Torsten Haferlach  
Michael Hallek  
Jörg Hasford  
Rüdiger Hehlmann  
Dieter Hoelzer (Editor-in-Chief)  
Per Ljungmann  
Dietger Niederwieser  
Susanne Saussele  
Hubert Serve  
Bengt Simonsson  
Theo J. M. de Witte

#### **6. Agreement:**

As an author of the Information Letter of the European LeukamieNet (ELN), I agree, to follow these editor statements of the Information Letter of the ELN.

Name:

\_\_\_\_\_

date

\_\_\_\_\_

sign